Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection

Emanuela M. Ghia, Sonia Jain, George F.Widhopf II, Laura Z. Rassenti, Michael J. Keating, William G. Wierda, John G. Gribben, Jennifer R. Brown, Kanti R. Rai, John C. Byrd, Neil E. Kay, Andrew W. Greaves, Thomas J. Kipps

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Fingerprint

Dive into the research topics of 'Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds